Humenza

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d

1 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

ANNEX I 
 

SUMMARY OF PRODUCT CHARACTERISTICS 
 



Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d

 
2 

1. NAME OF THE MEDICINAL PRODUCT 
 
HUMENZA suspension and emulsion for emulsion for injection 
Pandemic influenza vaccine (H1N1) (split virion, inactivated, adjuvanted) 
 
 
2. QUALITATIVE AND QUANTITATIVE COMPOSITION 
 
HUMENZA consists of two vials: one vial containing the antigen (suspension) and one vial containing 
the adjuvant (emulsion), which are mixed prior to administration. 
 
After mixing, 1 dose (0.5ml) contains: 
 
Split influenza virus*, inactivated containing antigen equivalent to: 
A/California/7/2009 (H1N1)-like strain (NYMC X-179A).......................................3.8 micrograms** 
 
* propagated in eggs 
** expressed in microgram haemagglutinin 
 
This vaccine complies with the WHO recommendation and EU decision for the pandemic. 
 
AF03 adjuvant composed of squalene (12.4 milligrams), sorbitan oleate (1.9 milligrams), 
polyoxyethylene cetostearyl ether (2.4 milligrams) and mannitol (2.3 milligrams)  
 
The suspension and emulsion, once mixed, form a multidose vaccine in a vial. See section 6.5 for the 
number of doses per vial. 
 
Excipients: 
The vaccine contains 11.3 micrograms thiomersal. 
 
For a full list of excipients, see section 6.1. 
 
 
3. PHARMACEUTICAL FORM 
 
Suspension and emulsion for emulsion for injection. 
The antigen is a colourless limpid to opalescent suspension.  
The adjuvant is a white opaque emulsion.  
 
 
4. CLINICAL PARTICULARS 
 
4.1 Therapeutic indications 
 
Prophylaxis of influenza in an officially declared pandemic situation (see sections 4.2 and 5.1). 
 
Pandemic influenza vaccine should be used in accordance with Official Guidance.  
 
4.2 Posology and method of administration 
 
Posology 
 
In the different age groups, there are limited data (adults aged 18 to 60 years), very limited data (adults 
aged 61 years and over, children aged 6 months to 17 years) or no data (children aged less than 6 
months) with HUMENZA as detailed in sections 4.4, 4.8 and 5.1. 
 



Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d

 
3 

Children from 3 years of age, adolescents and adults up to 60 years of age:  
One dose of 0.5 ml at an elected date. 
Immunogenicity data obtained at three weeks after administration of Humenza in clinical studies 
suggest that a single dose may be sufficient. 
If a second dose is administered there should be an interval of at least three weeks between the first 
and the second dose. 
 
Elderly above 60 years of age: 
One dose of 0.5 ml at an elected date. 
A second dose of vaccine should be given after an interval of at least three weeks. 
 
Children from 6 months of age to less than 3 years of age: 
One half-dose of 0.25 ml at an elected date. 
Immunogenicity data obtained in a limited number of children aged 6-35 months show that there is a 
further immune response to a second half-dose of 0.25 ml administered after an interval of three 
weeks. 
The use of a second half-dose should take into consideration the information provided in sections 4.4, 
4.8 and 5.1.  
 
Children below 6 months of age: 
Vaccination is currently not recommended in this age group. 
 
For further information, see section 5.1. 
 
It is recommended that subjects who receive a first dose of HUMENZA, complete the vaccination 
course with HUMENZA (see section 4.4). 
 
Method of administration 
 
Immunisation should be carried out by intramuscular injection (IM) preferably into the deltoid muscle 
or anterolateral thigh (depending on the muscle mass). 
 
For instructions for preparation, see section 6.6. 
 
4.3 Contraindications 
 
History of an anaphylactic (i.e. life-threatening) reaction to any of the constituents or trace residues 
(ovalbumin, egg and chicken proteins, neomycin, octoxinol-9, formaldehyde). If vaccination is 
considered to be necessary, facilities for resuscitation should be immediately available in case of need. 
 
See section 4.4. for Special warnings and special precautions for use. 
 
4.4 Special warnings and precautions for use 
 
Caution is needed when administering this vaccine to persons with a known hypersensitivity (other 
than anaphylactic reaction) to the active substance, to any of the excipients, to thiomersal, and to 
residues (ovalbumin, egg and chicken proteins, neomycin, octoxinol-9, formaldehyde). 
 
As with all injectable vaccines, appropriate medical treatment and supervision should always be 
readily available in case of a rare anaphylactic event following the administration of the vaccine. 
 
If the pandemic situation allows, immunisation shall be postponed in patients with severe febrile 
illness or acute infection. 
 
HUMENZA should under no circumstances be administered intravascularly. 
 



Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d

 
4 

There are no data with HUMENZA using the subcutaneous route. Therefore, healthcare providers 
need to assess the benefits and potential risks of administering the vaccine in individuals with 
thrombocytopenia or any bleeding disorder that would contraindicate intramuscular injection unless 
the potential benefit outweighs the risk of bleedings. 
 
There are no data on administration of AF03-adjuvanted vaccines before or following other types of 
influenza vaccines intended for pre-pandemic or pandemic use. 
 
Antibody response in patients with endogenous or iatrogenic immunosuppression may be insufficient. 
 
A protective immune response may not be elicited in all vaccinees (see section 5.1). 
 
Very limited data in children aged 6 to 35 months (N=96) who received two doses of 0.25 ml (half of 
the adult dose) with an interval of 3 weeks between doses indicate an increase in the rates of injection 
site reactions and general symptoms (see section 4.8.). In particular rates of fever (axillary temperature 
≥38°C) may increase considerably after the second dose. Therefore, monitoring of temperature and 
measures to lower fever (such as antipyretic medication as seems clinically necessary) are 
recommended in young children (e.g. up to approximately 8 years of age) after each vaccination. 
 
There are very limited safety and immunogenicity data available from clinical studies with 
HUMENZA in adults aged over 60 years of age. 
 
There are no safety, immunogenicity or efficacy data to support interchangeability of HUMENZA 
with other H1N1 pandemic vaccines.  
 
4.5 Interaction with other medicinal products and other forms of interaction 
 
There are no data on co-administration of HUMENZA with other vaccines. However, if 
co-administration with another vaccine is considered, immunisation should be carried out on separate 
limbs. It should be noted that the adverse reactions may be intensified. 
 
The immunological response may be diminished if the patient is undergoing immunosuppressant 
treatment. 
 
Following influenza vaccination, false-positive serology test results may be obtained by the ELISA 
method for antibody to human immunodeficiency virus-1 (HIV-1), hepatitis C virus and, especially, 
HTLV-1. In such cases, the Western blot method is negative.  These transitory false-positive results 
may be due to IgM production in response to the vaccine. 
 
4.6 Pregnancy and lactation 
 
No data have been generated in pregnant or lactating women with the vaccine HUMENZA or with any 
other vaccine containing adjuvant AF03. 
 
A reproductive and developmental toxicity study conducted in rabbits with HUMENZA showed no 
effects on embryo fetal development. 
 
The use of HUMENZA may be considered during pregnancy and lactation if this is thought to be 
necessary, taking into account official recommendations. 
 
4.7 Effects on ability to drive and use machines 
 
Some of the effects mentioned under section 4.8 “Undesirable Effects” may affect the ability to drive 
or use machines. 
 



Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d

 
5 

4.8 Undesirable effects 
 
• Clinical trials 
 
Adults and elderly: 
 
In an open-label clinical trial, two doses (0.5 ml) of HUMENZA have been administered at a 3-week 
interval in 153 subjects (99 adults and 54 elderly).  
 
Local and systemic reactions occurred within 7 days following any vaccine administration. These 
reactions were usually resolved spontaneously within 1 to 3 days after onset. The severity of these 
reactions was from grade 1 (mild) to grade 2 (moderate). The rate of grade 3 (severe) reactions was 
overall low (≤ 2%).  
 
The most frequent reaction was injection site pain.  
 
Overall, reactions were more frequent in adults than in elderly and less frequent after the second dose 
in both age groups. 
 
Adverse reactions reported following any vaccination are listed below according to the following 
frequency: 
 
Very common (≥1/10) 
Common (≥1/100 to <1/10) 
Uncommon (≥1/1,000 to <1/100) 
Rare (≥1/10,000 to <1/1,000) 
Very rare (<1/10,000) 
 
Nervous system disorders 
- Very common: headache 
 
Musculoskeletal and connective tissue disorders 
- Very common: myalgia 
 
General disorders and administration site conditions 
- Very common: injection site pain 
- Common: malaise, shivering, fever, injection site reactions such as induration, erythema, 

swelling, ecchymosis. 
 
Children and adolescent (from 3 to 17 years of age): 
In an open-label clinical trial, two doses (0.5 ml) of HUMENZA have been administered at a 3-week 
interval in 50 children from 3 to 8 years of age and 49 adolescents from 9 to 17 years of age. The 
safety has been assessed after each administration. 
 
Overall, reactions were more frequent in children and adolescents than in adults and elderly. 
 
Local and systemic reactions occurred within 7 days following any vaccine administration. These 
reactions were usually resolved spontaneously within 1 to 3 days after onset. 
 
The severity of the local and systemic reactions was mainly from grade 1 (mild) to grade 2 (moderate). 
The rate of grade 3 (severe) reactions was overall low (from 2 to 14% in children from 3 to 8 years of 
age and from 2 to 8.2% in adolescents from 9 to 17 years of age).  
 



Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d

 
6 

In children from 3 to 8 years of age, the most frequent reactions were injection site pain and injection 
site erythema. Overall, a higher frequency of injection site reactions and fever was reported in this age 
group compared to the adolescents. Moreover, a higher frequency of fever and headache was reported 
after the second dose than after the first dose.  
 
In adolescents from 9 to 17 years of age, the most frequent reactions were injection site pain and 
headache. A higher frequency of headache was reported in this age group compared to the children, 
adults and elderly. 
 
Percentages of subjects who reported the following adverse reactions after each dose are provided by 
age group in the table below: 
 
 Children (N=50) 

3 to 8 years of age 
Adolescents (N=49) 
9 to 17 years of age 

 1st dose 2nd dose 1st dose 2nd dose 
Injection site pain 80.0 % 74.0% 79.6% 67.3% 
Injection site erythema 36.0 % 38.0% 22.4% 22.4% 
Injection site swelling 20.0% 18.0% 12.2% 12.2% 
Injection site induration 18.0% 10.0% 10.2% 12.2% 
Injection site ecchymosis 18.0% 12.0% 4.1% 2.0% 
Fever (≥ 38°C) 4.0% 20.0% 6.1% 6.1% 
Headache 20.0% 32.0% 57.1% 42.9% 
Malaise 20.0% 36.0% 36.7% 32.7% 
Myalgia 32.0% 24.0% 36.7% 32.7% 
Shivering 16.0% 18.0% 26.5% 26.5% 
 
Regarding unsolicited reactions after any vaccination, injection site warmth (4%) was reported in 
children from 3 to 8 years of age and oropharyngeal pain (6.1%) was reported in adolescents from 9 to 
17 years of age. 
 
Children from 6 to 35 months of age: 
In an open-label clinical trial, two half-doses (0.25 ml) of HUMENZA have been administered at a 3-
week interval in 48 children from 6 to 11 months of age and in 48 children from 12 to 35 months of 
age.  
 
Local and systemic reactions occurred within 7 days following any vaccine administration. These 
reactions were usually resolved spontaneously within 1 to 3 days after onset. 
 
The severity of the local and systemic reactions was mainly from grade 1 (mild) to grade 2 (moderate). 
The rate of grade 3 (severe) reactions was overall low (from 6.5 to 8.3% in children from 6 to 11 
months of age and from 8.3 to 12.5% in children from 12 to 35 months of age).  
 
Overall, local and systemic reactions were less frequently observed in children from 6 to 35 months of 
age than in children from 3 to 8 years, except fever which was more frequently observed in children 
from 6 to 23 months. Overall, systemic reactions were more frequently reported in children from 6 to 
11 months compared to children from 12 to 23 months. 
 



Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d

 
7 

Percentages of subjects who reported the following adverse reactions after each dose are provided by 
age group in the table below: 
 
 Children (N=48) 

6 to 11 months 
Children (N=48) 
12 to 35 months  

 1st dose 2nd dose 1st dose 2nd dose  
Injection site 
pain/tenderness 

18.8% 28.3% 50.0% 29.2% 

Injection site erythema 10.4% 19.6% 14.6% 33.3% 
Injection site swelling 8.3% 6.5% 2.1% 12.5% 
Injection site induration 8.3% 21.7% 12.5% 12.5% 
Injection site ecchymosis 2.1% 4.3% 6.3% 6.3% 
   12 to 23 months 24 to 35 months 
   1st dose 2nd dose 1st dose 2nd dose 
Fever (≥ 38°C) 8.3% 32.6% 28.6% 7.1% 0.0% 11.8% 
Headache - - - - 2.9% 5.9% 
Malaise - - - - 17.6% 17.6% 
Myalgia - - - - 11.8% 17.6% 
Shivering - - - - 5.9% 17.6% 
Vomiting 25.0% 23.9% 7.1% 0.0% - - 
Abnormal crying  39.6% 37.0% 14.3% 14.3% - - 
Drowsiness 22.9% 30.4% 14.3% 28.6% - - 
Appetite lost 33.3% 30.4% 42.9% 21.4% - - 
Irritability 45.8% 50.0% 28.6% 28.6% - - 
 
Regarding unsolicited reactions after any vaccination, diarrhoea (4.3 %) was reported in children from 
6 to 11 months of age and cough (4.2 %) was reported in children from 12 to 35 months of age. 
 
• Post-marketing surveillance 
 
From post marketing surveillance with interpandemic trivalent vaccines, the following adverse events 
have been reported very rarely, even if an exact incidence rate cannot be precisely calculated: 
 
Blood and lymphatic system disorders: 
Transient thrombocytopenia, transient lymphadenopathy 
 
Immune system disorders:  
Allergic reactions, in rare cases leading to shock, angioedema 
 
Nervous system disorders: 
Neuralgia, paraesthesia, febrile convulsions, neurological disorders, such as encephalomyelitis, 
neuritis and Guillain-Barré syndrome 
 
Vascular disorders:  
Vasculitis associated in very rare cases with transient renal involvement 
 
Skin and subcutaneous tissue disorders: 
Generalised skin reactions including pruritus, urticaria or non-specific rash 
 
This medicinal product contains thiomersal (an organomercuric compound) as a preservative and 
therefore, it is possible that sensitisation reactions may occur (see section 4.4). 
 
4.9 Overdose 
 
No case of overdose have been reported. 
 



Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d

 
8 

 
5. PHARMACOLOGICAL PROPERTIES 
 
5.1 Pharmacodynamic properties 
 
Pharmacotherapeutic group: Influenza vaccines, ATC code: J07BB02. 
 
This medicinal product has been authorised under a so-called "conditional approval" scheme. 
This means that further evidence on this medicinal product is awaited. 
The European Medicines Agency will review any new information on the medicine and this Summary 
of Product Characteristics will be updated as necessary. 
 
This section describes the clinical experience with HUMENZA following administration of one or two 
vaccine doses (0.5 ml or 0.25 ml) at a 3-week interval. 
The immunogenicity 21 days after each dose has been assessed and is presented below for each age 
group according to the seroprotection rate, the seroconversion rate and the seroconversion factor, 
using haemagglutination inhibiting (HI) method. 
The seroprotection rate corresponds to the proportion of subjects achieving a post-vaccination titer 
≥1:40.  
The seroconversion rate corresponds to the proportion of subjects with a pre-vaccination titer <1:10 
achieving a post-vaccination titer ≥1:40, or the proportion of subjects with a ≥four-fold increase from 
pre- to post-vaccination titer. 
The seroconversion factor corresponds to the geometric mean of individual ratios (post-/pre-
vaccination titers). 
 
For all age groups: 
- Immunogenicity results observed with the seroneutralisation (SN) method reflect those observed 

with HI method. 
- No data on antibody persistence are currently available. 
 
Adults (from 18 to 60 years of age): 
In a clinical trial, the immunogenicity 21 days after each injection of HUMENZA given 21 days apart 
has been assessed in 99 adults. 
 



Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d

 
9 

The seroprotection rate, the seroconversion rate and the seroconversion factor, using 
haemagglutination inhibiting (HI) method, were as follows: 
 

 Adults 
18 to 60 years of age 

 Total enrolled 
subjects 
 N= 99 

Seronegative subjects 
prior to vaccination 

N= 55 
21 days after 1st dose   
Seroprotection rate* % 
 [95% CI] 

97.0 % 
 [91.4; 99.4] 

94.5 % 
 [84.9; 98.9] 

Seroconversion rate** % 
 [95% CI] 

93.9 % 
 [87.3; 97.7] 

94.5 % 
 [84.9; 98.9] 

Seroconversion factor***  
[95% CI] 

76.0 
 [56.6; 102] 

94.0  
[64.5; 137] 

21 days after 2nd dose   
Seroprotection rate* % 
 [95% CI] 

100 % 
 [96.3; 100] 

100 % 
 [96.3; 100] 

Seroconversion rate** % 
 [95% CI] 

99.0 % 
 [94.4; 100] 

100 % 
 [96.3; 100] 

Seroconversion factor***  
[95% CI] 

115  
[89.1; 147] 

178 
[134; 235] 

* Proportion of subjects achieving a post-vaccination titer ≥1:40 
** For subjects with a pre-vaccination titer <1:10, proportion of subjects with a post-vaccination titer 
≥1:40 and for subjects with a pre-vaccination titer ≥1:10, proportion of subjects with a ≥four-fold 
increase from pre- to post-vaccination titer 
*** Geometric mean of individual ratios (post-/pre-vaccination titers) 
 
Elderly (>60 years of age): 
In a clinical trial, the immunogenicity 21 days after each injection of HUMENZA given 21 days apart 
has been assessed in 54 elderly (29 elderly from 61 to 70 years of age, 18 elderly from 71 to 80 years 
of age and 7 elderly of 81 years of age and over). 
 



Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d

 
10 

The seroprotection rate, the seroconversion rate and the seroconversion factor, using HI method, were 
as follows: 
 

 Elderly 
61 to 70 years of age 

Elderly 
71 to 80 years of age 

Elderly 
81 years of age and over 

 Total 
enrolled 
subjects 
 N= 29 

Seronegative 
subjects prior 
to vaccination 

N= 14 

Total 
enrolled 
subjects 
 N= 18  

Seronegative 
subjects prior 
to vaccination 

N= 7  

Total 
enrolled 
subjects 

 N= 7  

Seronegative 
subjects prior 
to vaccination 

N= 1  
 21 days after 1st dose 
Seroprotection 
rate* % 
 [95% CI] 

86.2 % 
[68.3;96.1] 

78.6 % 
[49.2; 95.3] 

77.8 % 
[52.4;93.6] 

42.9 % 
 [9.9; 81.6] 

85.7 % 
[42.1;99.6] 

0.0 % 
 Not computed 

Seroconversion 
rate** % 
[95% CI] 

82.8 %  
[64.2;94.2] 

78.6 % 
[49.2; 95.3] 

72.2 %  
[46.5;90.3] 

42.9 % 
 [9.9; 81.6] 

42.9 % 
[9.9;81.6] 

0.0 % 
 Not computed 

Seroconversion 
factor***  
[95% CI] 

22.1  
[12.4;39.3] 

21.5  
[9.42; 49.2] 

14.5  
[5.93;35.6] 

4.20  
[1.99; 8.90] 

5.94  
[1.12;31.6] 

1.14  
Not computed 

21 days after 2nd dose  
Seroprotection 
rate* % 
 [95% CI] 

100 % 
[88.1;100] 

100 % 
[76.8; 100] 

94.4 % 
[72.7;99.9] 

85.7 % 
 [42.1; 99.6] 

85.7 % 
[42.1;99.6] 

0.0 % 
 Not computed 

Seroconversion 
rate** % 
 [95% CI] 

96.6 %  
[82.2;99.9] 

100 % 
[76.8; 100] 

94.4 % 
[72.7;99.9] 

85.7 % 
[42.1; 99.6] 

57.1 % 
[18.4;90.1] 

0.0 % 
 Not computed 

Seroconversion 
factor***  
[95% CI] 

39.7  
[25.3;62.2] 

45.3  
[23.1; 88.5] 

21.0  
[11.1;39.7] 

14.5  
[5.11; 41.1] 

8.41  
[1.93;36.7] 

2.00  
Not computed 

* Proportion of subjects achieving a post-vaccination titer ≥1:40 
** For subjects with a pre-vaccination titer <1:10, proportion of subjects with a post-vaccination titer 
≥1:40 and for subjects with a pre-vaccination titer ≥1:10, proportion of subjects with a ≥four-fold 
increase from pre- to post-vaccination titer 
*** Geometric mean of individual ratios (post-/pre-vaccination titers) 
 
Children and adolescents (from 3 to 17 years of age): 
In a clinical trial, the immunogenicity 21 days after each injection of HUMENZA given 21 days apart 
has been assessed in 50 children from 3 to 8 years of age and 49 adolescents from 9 to 17 years of age. 
 



Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d

 
11 

The seroprotection rate, the seroconversion rate and the seroconversion factor, using HI method, were 
as follows: 
 

 Children 
3 to 8 years of age 

Adolescents 
9 to 17 years of age 

 Total enrolled 
subjects 
 N= 50 

Total enrolled 
subjects 
 N= 49 

Seronegative subjects 
prior to vaccination 

N= 37 
 21 days after 1st dose    
Seroprotection rate* % 
 [95% CI] 

100 %  
[92.9; 100] 

100 % 
 [92.6; 100] 

100 % 
 [90.5; 100] 

Seroconversion rate** % 
 [95% CI] 

100 %  
[92.9; 100] 

100 % 
 [92.6; 100] 

100 % 
 [90.5; 100] 

Seroconversion factor***  
[95% CI] 

124  
[99.6; 156] 

177  
[130; 241] 

203  
[149; 276] 

21 days after 2nd dose    
Seroprotection rate* % 
[95% CI] 

100 %  
[92.7; 100] 

100 % 
 [92.7; 100] 

100 % 
 [90.5; 100] 

Seroconversion rate** % 
[95% CI] 

100 %  
[92.7; 100] 

100 % 
 [92.6; 100] 

100 % 
 [90.5; 100] 

Seroconversion factor***  
[95% CI] 

883  
[745; 1046] 

527  
[393; 706] 

745  
[620; 895] 

* Proportion of subjects achieving a post-vaccination titer ≥1:40 
** For subjects with a pre-vaccination titer <1:10, proportion of subjects with a post-vaccination titer 
≥1:40 and for subjects with a pre-vaccination titer ≥1:10, proportion of subjects with a ≥ four-fold 
increase from pre- to post-vaccination titer 
*** Geometric mean of individual ratios (post-/pre-vaccination titers) 
 
All children aged from 3 to 8 years were seronegative prior to vaccination. 
 
Children (from 6 to 35 months of age): 
In an open-label clinical trial, two half-doses (0.25 ml) of HUMENZA have been administered at a 
3-week interval in 48 children from 6 to 11 months of age and in 48 children from 12 to 35 months. 
 



Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d

 
12 

The immunogenicity 21 days after each half-dose (0.25 ml) of HUMENZA in term of the 
seroprotection rate, the seroconversion rate and the seroconversion factor, using HI method, were as 
follows: 
 

 Children 
(6 to 11 months of age) 

Children  
(12 to 35 months of age) 

 Total enrolled subjects 
 N= 48 

Total enrolled subjects 
 N= 48 

21 days after 1st dose 
Seroprotection rate* % 
 [95% CI] 

95.7 %  
[85.5; 99.5] 

97.8 %  
[88.5; 99.9] 

Seroconversion rate** % 
 [95% CI] 

95.7 %  
[85.5; 99.5] 

97.8 %  
[88.5; 99.9] 

Seroconversion factor***  
[95% CI] 

39.9  
[30.8; 51.7] 

50.7  
[38.1; 67.4] 

21 days after 2nd dose 
Seroprotection rate* % 
 [95% CI] 

100 %  
[91.8; 100] 

100 %  
[92.5; 100] 

Seroconversion rate** % 
 [95% CI] 

100 %  
[91.8; 100] 

100 %  
[92.5; 100] 

Seroconversion factor***  
[95% CI] 

602 
[495; 731] 

543 
[441; 670] 

* Proportion of subjects achieving a post-vaccination titer ≥1:40 
** For subjects with a pre-vaccination titer <1:10, proportion of subjects with a post-vaccination titer 
≥1:40 and for subjects with a pre-vaccination titer ≥1:10, proportion of subjects with a ≥ four-fold 
increase from pre- to post-vaccination titer 
*** Geometric mean of individual ratios (post-/pre-vaccination titers) 
 
All children aged from 6 to 35 months were seronegative prior to vaccination. 
 
Information from non-clinical studies 
A challenge ferret study showed vaccine similar protection after one or two human doses based on 
lung macroscopic examination, body weight loss (as indicator of disease after challenge) and viral 
loads in lungs and in the upper respiratory tract. 
 
The ability of one or two administrations of HUMENZA to protect ferrets against infection in the 
lungs was evaluated. Groups of 7 ferrets were immunized intramuscularly (IM) with one human dose 
of HUMENZA (3.8 µg of HA and full dose AF03) (at D21) or 2-dose administration of one human 
dose at 3-week intervals (at D0 and D21) and compared to a control group (AF03 adjuvant diluted in 
PBS). Four weeks after the last vaccine administration, ferrets were challenged with the wild type 
homologous strain A/H1N1/Netherlands/602/2009. 
A single administration of a human dose of HUMENZA elicited HI titers ≥ 80 and MN 
(Microneutralization) titers ≥ 160 specific to the vaccinal strain in 100% of vaccinated animals and a 
two-dose administration regimen markedly increased (at least a 5-fold increase) HI and MN antibody 
titers. A mean body weight loss of 20% was recorded in control group 4 days after infection. This 
body weight loss was reduced to ≤ 8% in animals that received 1 or 2 doses of HUMENZA. Four days 
after challenge, in the control group, 34% of the lungs were affected and presented lung lesions 
associated with high levels of virus replication in lung tissue (≥ 4.7 TCID50/g tissue).  



Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d

 
13 

In ferrets administered with one or two doses of HUMENZA, a significant reduction of lung damages 
(4 % or 1 % of affected lung, respectively) and of lung viral loads (more than 4 log10 reduction) was 
achieved resulting in 86% (6 out of 7 ferrets) or 100% of ferrets with no detectable virus in lungs, 
respectively. The protection against infection in the lungs was associated with vaccine-induced HI 
titers ≥ 40, a titer described in humans to be associated with protection against seasonal influenza. 
Viral shedding was assessed by measuring viral replication in both nasal and throat swabs and results 
demonstrated that HUMENZA was able to consistently reduce the viral load in the upper respiratory 
tract. 
 
5.2 Pharmacokinetic properties 
 
Not applicable. 
 
5.3 Preclinical safety data 
 
Available non clinical data obtained with the vaccine HUMENZA or with the same vaccine but with 
another strain (A/H5N1) revealed no special hazard for humans based on conventional  repeat dose 
toxicity studies, reproductive and developmental toxicity studies and an investigative 
pneumopathology study.  
 
Repeated injections of the vaccine induced moderate local inflammation in rabbits and no exacerbation 
of pneumonia after exposure to the parental wild-type virus in monkeys.  Rabbits dosed with vaccine, 
or with AF03 adjuvant alone, showed a slight increase of apoptosis / necrosis in the lachrymal tissues 
at doses higher than the human dose. Rabbits dams dosed with vaccine pre-mating and during 
gestation did not show any effects on embryofetal development. 
 
The adjuvant, AF03, was not mutagenic or clastogenic and induced transient inflammatory changes in 
repeat dose toxicity studies (in rats and rabbits). The reproductive and developmental toxicity studies 
conducted in rats and rabbits with AF03 did not show any effects on female fertility, pregnancy, 
embryofetal development or early postnatal development. 
 
6. PHARMACEUTICAL PARTICULARS 
 
6.1 List of excipients 
 
Antigen vial:  
Thiomersal 
Sodium chloride 
Potassium chloride 
Disodium phosphate dihydrate 
Potassium dihydrogen phosphate 
Water for injections 
 
Adjuvant vial: 
Sodium chloride 
Potassium chloride 
Disodium phosphate dihydrate 
Potassium dihydrogen phosphate 
Water for injections 
 
For adjuvant, see section 2. 
 
6.2 Incompatibilities 
 
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal 
products. 



Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d

 
14 

 
6.3 Shelf life 
 
6 months.  
After mixing, HUMENZA should be stored in a refrigerator (2°C-8°C) and should be used within 24 
hours. 
 
6.4 Special precautions for storage 
 
Store in a refrigerator (2°C-8°C). Do not freeze. 
For storage conditions after opening, see section 6.3.  
Keep the vials in the outer carton in order to protect from light. 
 
6.5 Nature and contents of container 
 
One pack containing: 
- One pack of 10 vials (type I glass) of 1.5 ml suspension (antigen) with stopper (chlorobutyl). 
- One pack of 10 vials (type I glass) of 4.5 ml emulsion (adjuvant) with stopper (chlorobutyl). 
 
Number of doses after mixing the content of antigen vial into the adjuvant vial: 10 doses of 0.5 ml. 
 
6.6 Special precautions for disposal and other handling 
 
HUMENZA consists of 2 separate vials:  
- One vial containing the antigen (suspension) 
- One vial containing the adjuvant (emulsion) 

 
Before use, the two components should be mixed. 
 
Instructions for mixing the vaccine: 
1. Before extemporaneous mix, the two vials (antigen and adjuvant) should be allowed to reach 

room temperature and must be gently swirled between hands and inspected visually for any 
foreign particulate matter and/or abnormal physical appearance. In the event of either being 
observed (including rubber particles from the stopper), the vaccine should be discarded. 

2. The vaccine is mixed by withdrawing with a sterile syringe and needle the entire content of the 
antigen vial and adding it into the adjuvant vial. 

3. After the addition of the antigen to the adjuvant, the mixture should be gently shaken by at least 
5 rotating movements. After mixing, the vaccine is a white opaque emulsion. 

4. The volume of HUMENZA after mixing is at least 6 ml and allows the withdrawal of several 
doses (multidose vial). For the dose to be administered, see recommended posology in section 
4.2. 

5. After mixing HUMENZA should be stored in a refrigerator (2°C-8°C) (never place in the 
freezer) and should be used within 24 hours.  

6. To facilitate tracking and timely disposal of partially used vials, it is suggested that the date and 
hour of mixing be clearly written on the label of adjuvant vial. 

 
Instructions for the administration of the vaccine: 
1. Before injection the vaccine should be allowed to reach room temperature by gently swirling the 

vial between hands (not more than 5 minutes). 
2. Prior to each administration, the multidose vial should be gently shaken by at least 5 rotating 

movements.  
3. The content of the multidose vial as well as the content of the syringe after withdrawal should 

be inspected visually. The vaccine is of a white opaque emulsion appearance. If deviations from 
this description and/or any foreign particulate matter are observed (including rubber particles 
from the stopper), the vaccine should be discarded.  



Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d

 
15 

4. Each vaccine dose of 0.5 ml or 0.25 ml (half-dose) is withdrawn with a new sterile syringe for 
injection and administered intramuscularly. 

 
A partially used multidose vial must be discarded immediately if: 
- Sterile dose withdrawal has not been fully observed. 
- There is any suspicion that the partially used vial has been contaminated. 
- There is visible evidence of contamination, such as change in appearance. 
 
In order to keep the traceability of the product received by each vaccinee the name of the vaccine and 
the lot number should be recorded by using the stickers provided in the pack containing both the 
antigen and adjuvant vials. 
 
Any unused product or waste material should be disposed of in accordance with local requirements. 
 
 
7. MARKETING AUTHORISATION HOLDER 
 
Sanofi Pasteur SA 
2, avenue Pont Pasteur 
F-69007 Lyon 
France 
 
 
8. MARKETING AUTHORISATION NUMBER(S) 
 
 
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 
 
 
10. DATE OF REVISION OF THE TEXT 
 
Detailed information on this medicinal product is available on the website of the European Medicines 
Agency  (http://www.ema.europa.eu). 



Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d

 
16 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

ANNEX II 
 

A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE 
SUBSTANCE AND MANUFACTURING AUTHORISATION 
HOLDERS RESPONSIBLE FOR BATCH RELEASE 

 
B. CONDITIONS OF THE MARKETING AUTHORISATION 

 
C. SPECIFIC OBLIGATIONS TO BE FULFILLED BY THE 

MARKETING AUTHORISATION HOLDER 
 
 



Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d

 
17 

A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND 
MANUFACTURING AUTHORISATION HOLDERS RESPONSIBLE FOR BATCH 
RELEASE 

 
Name and address of the manufacturers of the biological active substance 
 
sanofi pasteur 
Parc Industriel d’Incarville 
27100 Val-de-Reuil 
France 
 
sanofi pasteur 
Campus Mérieux 
1541, avenue Marcel Mérieux 
69280 Marcy l’Etoile 
France 
 
Name and address of the manufacturers responsible for batch release 
 
sanofi pasteur 
Parc Industriel d’Incarville 
27100 Val-de-Reuil 
France 
 
sanofi pasteur 
Campus Mérieux 
1541, avenue Marcel Mérieux 
69280 Marcy l’Etoile 
France 
 
The printed package leaflet of the medicinal product must state the name and address of the 
manufacturer responsible for the release of the concerned batch. 
 
 
B. CONDITIONS OF THE MARKETING AUTHORISATION 
 
• CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON 

THE MARKETING AUTHORISATION HOLDER 
 
Medicinal product subject to medical prescription. 
 
HUMENZA can only be marketed when there is an official WHO/EU declaration of an influenza 
pandemic, on the condition that the Marketing Authorisation Holder for HUMENZA takes due 
account of the officially declared pandemic strain. 
 
• CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND 

EFFECTIVE USE OF THE MEDICINAL PRODUCT 
 
• The MAH shall agree with Member States to measures facilitating the identification and 

traceability of the A/H1N1 pandemic vaccine administered to each patient, in order to minimise 
medication errors and aid patients and health care professionals to report adverse reactions. This 
may include the provision by the MAH of stickers with invented name and batch number with 
each pack of the vaccine. 

• The MAH shall agree with Member States on mechanisms allowing patients and health care 
professionals to have continuous access to updated information regarding HUMENZA. 



Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d

 
18 

• The MAH shall agree with Member Sates on the provision of a targeted communication to 
healthcare professionals which should address the following: 
• The correct way to prepare the vaccine prior to administration. 
• Adverse events to be prioritised for reporting, i.e. fatal and life-threatening adverse 

reactions, unexpected severe adverse reactions, adverse events of special interest (AESI). 
• The minimal data elements to be transmitted in individual case safety reports in order to 

facilitate the evaluation and the identification of the vaccine administered to each subject, 
including the invented name, the vaccine manufacturer and the batch number. 

• If a specific notification system has been put in place, how to report adverse reactions. 
 
• OTHER CONDITIONS 
 
Official batch release: in accordance with Article 114 of Directive 2001/83/EC as amended, the 
official batch release will be undertaken by a state laboratory or a laboratory designated for that 
purpose. 
 
Pharmacovigilance system 
The MAH must ensure that the system of pharmacovigilance, as described in version 10.0 
presented in Module 1.8.1. of the Marketing Authorisation Application, is in place and 
functioning before the product is placed on the market and for as long as the marketed product 
remains in use. 
 
PSUR submission during the influenza pandemic: 
 
During a pandemic situation, the frequency of submission of periodic safety update reports specified 
in Article 24 of Regulation (EC) No 726/2004 will not be adequate for the safety monitoring of a 
pandemic vaccine for which high levels of exposure are expected within a short period of time. Such 
situation requires rapid notification of safety information that may have the greatest implications for 
benefit-risk balance in a pandemic. Prompt analysis of cumulative safety information, in light of the 
extent of exposure, will be crucial for regulatory decisions and protection of the population to be 
vaccinated. The MAH shall submit on a monthly basis a simplified periodic safety update report with 
the timelines, format and content as defined in the CHMP Recommendations for the 
Pharmacovigilance Plan as part of the Risk Management Plan to be submitted with the Marketing 
Authorisation Application for a Pandemic Influenza Vaccine (EMA/359381/2009) and any subsequent 
update. 
 
Risk Management Plan 
The MAH commits to performing the studies and additional pharmacovigilance activities 
detailed in the Pharmacovigilance Plan, as agreed in version 7.0 of the Risk Management Plan 
(RMP) presented in Module 1.8.2. of the Marketing Authorisation Application and any 
subsequent updates of the RMP agreed by the CHMP. 
 
 
C. SPECIFIC OBLIGATIONS TO BE FULFILLED BY THE MARKETING 

AUTHORISATION HOLDER 
 
The Marketing Authorisation Holder shall complete the following programme of studies within the 
specified time frame, the results of which shall form the basis of the annual reassessment of the 
benefit/risk profile. 
 



Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d

 
19 

Clinical Independently of the cohort safety study (9,000 subjects), 
the MAH commits to implement a post-licensure 
prospective clinical safety study (N=3,000 subjects from 6 
months of age). 
The RMP will be updated accordingly to reflect this study 
within 15 calendar days of the receipt of the opinion. 

Initiation of the 
study by July 
2010 
 

Pharmacovigilance The MAH commits to update the observational study 
protocol to screen for auto-antibodies those patients 
presenting visual or ocular events during the study follow-
up. 

Prospective 
cohort safety 
study protocol 
update to be 
submitted within 
one week of 
Commission 
Decision 
granting 
Marketing 
Authorization. 

Pharmacovigilance The MAH commits to submit the data from pregnancy 
registry as described in the RMP. 

Results to be 
provided in the 
simplified PSUR. 

Pharmacovigilance The MAH will submit the results of a prospective cohort 
safety study in at least 9,000 patients in different age 
groups, including immunocompromised subjects, in 
accordance with the protocol submitted with the Risk 
Management Plan. 
 

Interim and final 
results will be 
submitted in 
accordance with 
the protocol. 

Pharmacovigilance The MAH commits to present a plan for the definition of the 
sources to collect safety data on immunocompromised 
patient within the prospective cohort safety study. 
 

Prospective 
cohort safety 
study protocol 
update to be 
submitted within 
one week of 
Commission 
Decision 
granting 
Marketing 
Authorization. 
 

Pharmacovigilance The MAH will submit the results of the GBS surveillance 
study. 
 

Interim and final 
results will be 
submitted in 
accordance with 
the protocol. 



Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d

 
20 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

ANNEX III 
 

LABELLING AND PACKAGE LEAFLET 
 



Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d

 
21 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

A. LABELLING 



Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d

 
22 

 
PARTICULARS TO APPEAR ON THE OUTER PACKAGING  
PACK CONTAINING 1 PACK OF 10 VIALS OF SUSPENSION (ANTIGEN) AND 1 PACK 
OF 10 VIALS OF EMULSION (ADJUVANT) 
 
 
1. NAME OF THE MEDICINAL PRODUCT 
 
HUMENZA suspension and emulsion for emulsion for injection 
Pandemic influenza vaccine (H1N1) (split virion, inactivated, adjuvanted) 
 
 
2. STATEMENT OF ACTIVE SUBSTANCE(S) 
 
After mixing, 1 dose (0.5 ml) contains: 
Split influenza virus*, inactivated, containing antigen equivalent to: 
A/California/7/2009 (H1N1)-like strain (NYMC X-179A)...........................................3.8 micrograms** 
 
* propagated in eggs 
** haemagglutinin 
 
AF03 adjuvant composed of squalene, sorbitan oleate, polyoxyethylene cetostearyl ether and mannitol 
 
 
3. LIST OF EXCIPIENTS 
 
Excipients:  
Thiomersal  
Sodium chloride  
Potassium chloride  
Disodium phosphate dihydrate  
Potassium dihydrogen phosphate  
Water for injections 
 
 
4. PHARMACEUTICAL FORM AND CONTENTS 
 
Suspension and emulsion for emulsion for injection  
10 vials of suspension (antigen) 
10 vials of emulsion (adjuvant) 
 
Number of doses after mixing the content of antigen vial into the adjuvant vial: 10 doses of 0.5 ml. 
 
 
5. METHOD AND ROUTE(S) OF ADMINISTRATION 
 
Intramuscular use 
Shake before use 
Read the package leaflet before use 
 
 



Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d

 
23 

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 
OF THE REACH AND SIGHT OF CHILDREN 

 
Keep out of the reach and sight of children 
 
 
7. OTHER SPECIAL WARNING(S), IF NECESSARY 
 
MIX THE ANTIGEN INTO THE ADJUVANT VIAL BEFORE USE 
 
 
8. EXPIRY DATE 
 
EXP MM/YYYY 
 
 
9. SPECIAL STORAGE CONDITIONS 
 
Store in a refrigerator. Do not freeze. 
Keep the vials in the outer carton in order to protect from light. 
After mixing, store in a refrigerator and use within 24 hours. 
 
 
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 

OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 
APPROPRIATE 

 
Dispose of in accordance with local regulations. 
 
 
11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER 
 
Sanofi Pasteur SA 
2, avenue Pont Pasteur 
69007 Lyon - France 
 
 
12. MARKETING AUTHORISATION NUMBER(S)  
 
 
 
13. BATCH NUMBER 
 
Lot 
 
 
14. GENERAL CLASSIFICATION FOR SUPPLY 
 
Medicinal product subject to medical prescription. 
 
 
15. INSTRUCTIONS ON USE 
 
 



Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d

 
24 

 
16. INFORMATION IN BRAILLE 
 
Justification for not including Braille accepted 



Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d

 
25 

 
PARTICULARS TO APPEAR ON THE OUTER PACKAGING  
PACK OF 10 VIALS OF SUSPENSION (ANTIGEN) 
 
 
1. NAME OF THE MEDICINAL PRODUCT 
 
Antigen for HUMENZA suspension for injection 
Pandemic influenza vaccine (H1N1)  
 
 
2. STATEMENT OF ACTIVE SUBSTANCE(S) 
 
Split influenza virus*, inactivated, containing antigen equivalent to: 
A/California/7/2009 (H1N1)-like strain (NYMC X-179A)..............................................................30 µg** 
                  For 1 ml  
* propagated in eggs 
** haemagglutinin 
 
 
3. LIST OF EXCIPIENTS 
 
Excipients: thiomersal, sodium chloride, potassium chloride, disodium phosphate dihydrate, potassium 
dihydrogen phosphate and water for injections. 
 
 
4. PHARMACEUTICAL FORM AND CONTENTS 
 
Suspension for injection  
10 vials  
 
 
5. METHOD AND ROUTE(S) OF ADMINISTRATION 
 
Intramuscular use 
Read the package leaflet before use 
 
 
6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 

OF THE REACH AND SIGHT OF CHILDREN 
 
Keep out of the reach and sight of children 
 
 
7. OTHER SPECIAL WARNING(S), IF NECESSARY 
 
MIX INTO THE ADJUVANT VIAL BEFORE USE 
 
 
8. EXPIRY DATE 
 
EXP MM/YYYY 
 
 



Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d

 
26 

9. SPECIAL STORAGE CONDITIONS 
 
Store in a refrigerator. Do not freeze. 
Keep the vials in the outer carton in order to protect from light. 
 
 
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 

OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 
APPROPRIATE 

 
Dispose of in accordance with local regulations. 
 
 
11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER 
 
Sanofi Pasteur SA 
2, avenue Pont Pasteur 
69007 Lyon - France 
 
 
12. MARKETING AUTHORISATION NUMBER(S)  
 
 
13. BATCH NUMBER 
 
Lot 
 
 
14. GENERAL CLASSIFICATION FOR SUPPLY 
 
Medicinal product subject to medical prescription. 
 
 
15. INSTRUCTIONS ON USE 
 
 
16. INFORMATION IN BRAILLE 
 
Justification for not including Braille accepted 



Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d

 
27 

 
PARTICULARS TO APPEAR ON THE OUTER PACKAGING  
PACK OF 10 VIALS OF EMULSION (ADJUVANT) 
 
 
1. NAME OF THE MEDICINAL PRODUCT 
 
Adjuvant for HUMENZA emulsion for injection  
 
 
2. STATEMENT OF ACTIVE SUBSTANCE(S) 
 
AF03 adjuvant composed of squalene (33 mg), sorbitan oleate (4.9 mg), polyoxyethylene cetostearyl 
ether (6.3 mg), mannitol (6.1 mg) per 1 ml  
 
 
3. LIST OF EXCIPIENTS 
 
Excipients: sodium chloride, potassium chloride, disodium phosphate dihydrate, potassium 
dihydrogen phosphate and water for injections. 
 
 
4. PHARMACEUTICAL FORM AND CONTENTS 
 
Emulsion for injection  
10 vials 
After mixing: 10 doses of 0.5 ml per vial. 
 
 
5. METHOD AND ROUTE(S) OF ADMINISTRATION 
 
Intramuscular use. 
Read the package leaflet before use. 
 
 
6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 

OF THE REACH AND SIGHT OF CHILDREN 
 
Keep out of the reach and sight of children. 
 
 
7. OTHER SPECIAL WARNING(S), IF NECESSARY 
 
MIX WITH THE ANTIGEN BEFORE USE 
 
 
8. EXPIRY DATE 
 
EXP MM/YYYY 
 
 



Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d

 
28 

9. SPECIAL STORAGE CONDITIONS 
 
Store in a refrigerator. Do not freeze. 
Keep the vials in the outer carton in order to protect from light. 
After mixing: use within 24 hours. 
 
 
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 

OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 
APPROPRIATE 

 
Dispose of in accordance with local regulations. 
 
11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER 
 
Sanofi Pasteur SA 
2, avenue Pont Pasteur 
69007 Lyon - France 
 
 
12. MARKETING AUTHORISATION NUMBER(S)  
 
 
13. BATCH NUMBER 
 
Lot 
 
 
14. GENERAL CLASSIFICATION FOR SUPPLY 
 
Medicinal product subject to medical prescription. 
 
 
15. INSTRUCTIONS ON USE 
 
 
16. INFORMATION IN BRAILLE 
 
Justification for not including Braille accepted 



Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d

 
29 

 
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS 
SUSPENSION VIAL (ANTIGEN) 
 
 
1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION 
 
Antigen for HUMENZA 
Pandemic influenza vaccine (H1N1) 
 
 
2. METHOD OF ADMINISTRATION 
 
Mix into the adjuvant vial before use. 
 
 
3. EXPIRY DATE 
 
EXP MM/YYYY 
 
 
4. BATCH NUMBER 
 
Lot 
 
 
5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 
 
1.5 ml 
 
 
6. OTHER 
 
Sanofi Pasteur 



Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d

 
30 

 
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS 
EMULSION VIAL (ADJUVANT) 
 
 
1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION 
 
Adjuvant for HUMENZA emulsion for injection 
IM 
 
 
2. METHOD OF ADMINISTRATION 
 
 
3. EXPIRY DATE 
 
EXP MM/YYYY 
 
 
4. BATCH NUMBER 
 
Lot 
 
 
5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 
 
4.5 ml 
After mixing with the antigen: 10 doses of 0.5 ml 
 
 
6. OTHER 
 
Sanofi Pasteur 
 



Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d

 
31 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

B. PACKAGE LEAFLET 
 



Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d

 
32 

PACKAGE LEAFLET: INFORMATION FOR THE USER 
 

HUMENZA Suspension and emulsion for emulsion for injection 
Pandemic influenza vaccine (H1N1) (split virion, inactivated, adjuvanted) 

 
 

For the most up-to-date information please consult the website of the European Medicines 
Agency : http://www.ema.europa.eu/. 

 
 
Read all of this leaflet carefully before you receive this vaccine. 
- Keep this leaflet. You may need to read it again. 
- If you have any further questions, ask your doctor or nurse. 
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, 

please tell your doctor. 
 
 
In this leaflet: 
1. What HUMENZA is and what it is used for 
2. Before you receive HUMENZA 
3. How HUMENZA is given 
4. Possible side effects 
5. How to store HUMENZA 
6. Further information 
 
 
1. WHAT HUMENZA IS AND WHAT IT IS USED FOR 
 
HUMENZA is a vaccine to prevent pandemic influenza (flu).  
 
Pandemic flu is a type of influenza that occurs every few decades and which spreads rapidly around 
the world. The symptoms (signs) of pandemic flu are similar to those of an ordinary flu but may be 
more severe. 
 
When a person is given the vaccine, the immune system (the body’s natural defence system) will 
produce its own protection (antibodies) against the disease. None of the ingredients in the vaccine can 
cause flu. 
 
 
2. BEFORE YOU RECEIVE HUMENZA 
 
You should not receive HUMENZA: 
- if you have previously had a sudden life-threatening allergic reaction to any ingredient of 

HUMENZA (these are listed at the end of the leaflet) or to any of the substances that may be 
present in trace amounts as follows: ovalbumin, egg and chicken proteins, neomycin, 
octoxinol-9, formaldehyde. Signs of an allergic reaction may include itchy skin rash, shortness 
of breath and swelling of the face or tongue. However, in a pandemic situation, it may be 
appropriate for you to have the vaccine provided that appropriate medical treatment is 
immediately available in case of an allergic reaction. 

 
If you are not sure, talk to your doctor or nurse before having this vaccine. 
 



Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d

 
33 

Take special care with HUMENZA: 
- if you have had any allergic reaction other than a sudden life-threatening allergic reaction to any 

ingredient contained in the vaccine, to thiomersal, ovalbumin, egg and chicken proteins, 
neomycin, octoxinol-9, formaldehyde (see section 6. Further information). 

- if you have a severe infection with a high temperature (over 38°C). If this applies to you then 
your vaccination will usually be postponed until you are feeling better. A minor infection such 
as a cold should not be problem, but your doctor should advise whether you could still be 
vaccinated with HUMENZA, 

- if you are having a blood test to look for evidence of infection with certain viruses. In the first 
few weeks after vaccination with HUMENZA the results of these tests may not be correct. Tell 
the doctor requesting these tests that you have recently been given HUMENZA. 

- as with all vaccines, HUMENZA may not fully protect all persons who are vaccinated. 
 
In any of these cases, TELL YOUR DOCTOR OR NURSE, as vaccination may not be recommended, 
or may need to be delayed. 
 
Please inform your doctor or nurse if you have a bleeding problem or bruise easily. 
 
Children below 6 months of age: 
HUMENZA is not recommended in children below 6 months of age.  
 
Taking other medicines 
Please tell your doctor or nurse if you are taking or have recently taken any other medicines, including 
medicines obtained without a prescription or have recently been given any other vaccine. 
 
There is no information on administration of the vaccine HUMENZA with other vaccines. 
However, if this cannot be avoided, the vaccines should be injected into separate limbs. In such cases, 
you should be aware that the side effects may be more intense. 
 
Pregnancy and breast-feeding 
Tell your doctor if you are pregnant, think you may be pregnant, plan to become pregnant or if you are 
breastfeeding. You should discuss with your doctor whether you should receive HUMENZA. 
 
Driving and using machines 
Some of the effects mentioned under section 4 “Possible side effects” may affect the ability to drive or 
use machines. 
 
Important information about some of the ingredients of HUMENZA 
This medicine contains thiomersal as a preservative and it is possible that you may experience an 
allergic reaction. Tell the doctor if you have any known allergies. 
 
 
3. HOW HUMENZA IS GIVEN 
 
Your doctor or nurse will administer the vaccine in accordance with official recommendations. 
 
The vaccine will be injected into a muscle, preferably in the upper arm or the front of the thigh 
(depending on the muscle mass).  
 
Children from 3 years of age, adolescents and adults up to 60 years of age:  
One dose of 0.5 ml of the vaccine will be given. 
Clinical data suggest that a single dose may be sufficient. 
If a second dose is administered there should be an interval of at least three weeks between the first 
and second dose. 
 



Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d

 
34 

Elderly above 60 years of age: 
One dose of 0.5 ml of the vaccine will be given. 
A second dose of vaccine should be given after an interval of at least 3 weeks. 
 
Children from 6 months to less than 3 years of age: 
One half-dose of 0.25 ml of the vaccine will be given. 
If a second dose of 0.25 ml is given, this will be administered at least three weeks after the first dose.  
 
Children below 6 months of age: 
Vaccination is currently not recommended in this age group 
 
When HUMENZA is given for the first dose, it is recommended that HUMENZA (and not another 
vaccine against H1N1) be given for the complete vaccination course. 
 
 
4. POSSIBLE SIDE EFFECTS 
 
Like all medicines, HUMENZA can cause side effects, although not everybody gets them. 
 
Allergic reactions may occur following vaccination, in rare cases leading to shock. Doctors are aware 
of this possibility and have emergency treatment available for use in such cases. 
 
The frequency of possible side effects listed below is defined using the following convention: 
 
Very common (affects more than 1 user in 10) 
Common (affects 1 to 10 users in 100) 
Uncommon (affects 1 to 10 users in 1,000) 
Rare (affects 1 to 10 users in 10,000) 
Very rare (affects less than 1 user in 10,000) 
 
During a clinical study conducted with HUMENZA in adults and elderly, the side effects listed below 
have been observed. 
Very common: headache, muscular pain, injection site pain. 
Common: feeling generally unwell, shivering, fever. At the injection site: hardness, redness, swelling, 
bruising. 
 
During clinical studies conducted with HUMENZA in children and adolescents, the side effects listed 
below have been observed. 
Adolescent from 9 to 17 years old: 
Very common: headache, feeling generally unwell, muscular pain, shivering. At the injection site: 
pain, redness, swelling, hardness. 
Common: fever, sore throat, injection site bruising. 
 
Children from 3 to 8 years old: 
Very common: feeling generally unwell, muscular pain, headache, shivering, fever. At the injection 
site: pain, redness, swelling, bruising, hardness. 
Common: injection site warmth. 
 
Children from 24 to 35 months old: 
Very common: feeling generally unwell, muscular pain, shivering, fever. At the injection site: pain, 
redness, hardness, swelling. 
Common: injection site bruising, headache, cough.  
 



Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d

 
35 

Children from 12 to 23 months old: 
Very common: appetite lost, irritability, drowsiness, fever, abnormal crying. At the injection site: pain, 
redness, hardness, swelling. 
Common: injection site bruising, vomiting, cough.  
 
Children from 6 to 11 months old: 
Very common: irritability, crying abnormal, appetite lost, drowsiness, fever, vomiting. At the injection 
site: pain, redness, hardness, swelling. 
Common: injection site bruising, diarrhoea. 
 
In all age goups, the side effects listed above usually disappeared without treatment within 1 to 3 days 
after onset. 
 
The side effects listed below have occurred in the days or weeks after vaccination with vaccines given 
routinely every year to prevent flu. These side effects may occur with HUMENZA. 
Very rare: 
- Skin reactions that may spread throughout the body including itchiness of the skin (pruritus, 
urticaria), rash. 
- Side effects related to the central nervous system: 

• Pain located on the nerve route (neuralgia), 
• Differences in the perception of touch, pain, heat and cold (paraesthesia), 
• Convulsions associated with fever, 
• Neurological disorders that may result in stiff neck, confusion, numbness, pain and weakness 

of the limbs, loss of balance, loss of reflexes, paralysis of part or all the body 
(encephalomyelitis, neuritis, Guillain-Barré Syndrome).  

- Temporary reduction in the number of certain types of particles in the blood called platelets; a 
low number of these can result in excessive bruising or bleeding (transient thrombocytopenia), 
temporary swelling of the glands in the neck, armpit or groin (transient lymphadenopathy). 
- Allergic reactions:  

• In rare cases leading to shock (a failure of the circulatory system to maintain adequate blood 
flow to the different organs leading to medical emergency). 

• Including swelling most apparent in the head and neck, including the face, lips, tongue, throat 
or any other part of the body (angioedema) in very rare cases. 

- Vessel inflammation (vasculitis) which may result in skin rashes and in very rare cases in 
temporary kidney problems. 
 
If any of these side effects occur, please tell your doctor or nurse immediately. 
 
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please 
tell your doctor. 
 
 
5. HOW TO STORE HUMENZA 
 
Keep out of the reach and sight of children. 
 
Before the vaccine is mixed: 
 
Do not use the antigen (suspension) and the adjuvant (emulsion) after the expiry date which is stated 
on the carton and the label after EXP. The expiry date refers to the last day of that month. 
 
Store in a refrigerator (2°C – 8°C). 
Do not freeze. 
Keep the vial in the outer carton in order to protect from light. 
 



Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d

 
36 

After the vaccine is mixed: 
 
HUMENZA should be stored in a refrigerator (2°C-8°C) and should be used within 24 hours 
 
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to 
dispose of medicines no longer required. These measures will help to protect the environment. 
 
 
6. FURTHER INFORMATION 
 
What HUMENZA contains 
 
HUMENZA consists of two vials: one vial containing the antigen (suspension) and one vial containing 
the adjuvant (emulsion), which are mixed prior to use. 
 
After mixing:  
- Active substance: 
Split Influenza virus*, inactivated, containing antigen equivalent to: 
A/California/7/2009 (H1N1)-like strain (NYMC X179A)….....................................3.8 micrograms** 
 per 0.5 ml dose 
* propagated in eggs 
** expressed in microgram haemagglutinin 
 
This vaccine complies with the WHO recommendation and EU decision for the pandemic. 
 
- Adjuvant: 
The adjuvant (AF03) is composed of squalene (12.4 milligrams), sorbitan oleate (1.9 milligrams), 
polyoxyethylene cetostearyl ether (2.4 milligrams) and mannitol (2.3 milligrams), per 0.5 ml dose 
 
- Other ingredients: 
The other ingredients are: thiomersal (11.3 micrograms per 0.5 ml dose), sodium chloride, potassium 
chloride, disodium phosphate dihydrate, potassium dihydrogen phosphate and water for injections. 
 
What HUMENZA looks like and contents of the pack 
 
One pack contains: 
- One pack containing 10 vials of 1.5 ml of suspension (antigen). 
- One pack containing 10 vials of 4.5 ml of emulsion (adjuvant). 
 
The antigen is a colourless limpid to opalescent suspension. 
The adjuvant is a white opaque emulsion.  
 
After mixing the content of antigen vial into the adjuvant vial, HUMENZA is an emulsion for 
injection in a multidose vial containing 10 doses of 0.5 ml. The emulsion is white, opaque. 
 
Marketing Authorisation Holder  
 
Sanofi Pasteur SA – 2, avenue Pont Pasteur – F-69007 Lyon – France 
 
Manufacturer 
 
Sanofi pasteur - Parc Industriel d’Incarville – F-27100 Val-de-Reuil – France 
Sanofi pasteur - Campus Mérieux – 1541, avenue Marcel Mérieux – F-69280 Marcy l’Etoile – France 
 
For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: 
 



Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d

 
37 

België/Belgique/Belgien 
Sanofi Pasteur MSD 
Tél/Tel: +32 2 726.9584 
 

Luxembourg/Luxemburg 
Sanofi Pasteur MSD 
Tél: +32 2 726.9584 
 

България 
Sanofi Pasteur Bulgaria  
Teл.: +359 2 980 08 33 
 

Magyarország 
sanofi-aventis zrt 
Tel.: +36 1 505 1889 
 

Česká republika 
Sanofi-aventis, s.r.o. 
Tel.: +420 233 086 387 
Tel: +420 233 086 111 
  

Malta 
Cherubino Ltd 
Tel.: +356 21 343270 
 

Danmark 
Sanofi Pasteur MSD 
Tlf: +45 23 32 69 29 
 

Nederland 
Sanofi Pasteur MSD 
Tel: +31.23.567.96.00 
 

Deutschland 
Sanofi Pasteur MSD GmbH 
Tel: +49 6224.594.0 
 

Norge 
Sanofi Pasteur MSD 
Tlf: +47.67.50.50.20 
 

Eesti 
Sanofi-Aventis Estonia LLC 
Tel.: +372 627 3473 
 

Österreich 
Sanofi Pasteur MSD GmbH 
Tel: +43.1.866.70.22.202 
 

Ελλάδα 
ΒΙΑΝΕΞ Α.Ε.  
Τηλ: +30.210.8009111  
 

Polska 
Sanofi Pasteur Sp. z o.o. 
Tel.: +48 22 280 05 00 
 

España 
Sanofi Pasteur MSD S.A. 
Tel: +34.91.371.78.00 
 

Portugal 
Sanofi Pasteur MSD, SA 
Tel: +351 21 470 4550 
 

France 
Sanofi Pasteur MSD SNC 
Tél: +33.4.37.28.40.00 
 

România 
Sanofi Aventis Romania SRL 
Tel.: +40 21 3047 463 
 

Ireland 
Sanofi Pasteur MSD Ltd 
Tel: +353 1 468 5600 
 

Slovenija 
ALPE s.p. 
Tel.: +386 1 432 62 38 
 

Ísland 
Sanofi Pasteur MSD 
Sími: +32.2.726.95.84 
 

Slovenská republika 
Intecpharma 
Tel.: +421 2 547 89 166 
 

Italia 
Sanofi Pasteur MSD Spa 
Tel: +39 06.664.09.211 
 

Suomi/Finland 
Sanofi Pasteur MSD 
Puh/Tel: +358.9.565.88.30 
 

Κύπρος 
Γ. Α. Σταμάτης & Σια Λτδ. 
Τηλ.: +357 - 22 76 62 76    
 

Sverige 
Sanofi Pasteur MSD 
Tel: +46.8.564.888.60 
 



Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d

 
38 

Latvija 
Sanofi Pasteur GmbH Representative Ofice 
Tel.: +371 671 14978 
 

United Kingdom 
Sanofi Pasteur MSD Ltd 
Tel: +44.1.628.785.291 
 

Lietuva 
Sanofi pasteur, vaccines division of    
UAB « SANOFI-AVENTIS LIETUVA » 
Tel.: +370 5 2730967  
 

 

 
This leaflet was last approved in {MM/YYYY} 
 
HUMENZA has been given "conditional approval". 
This means that there is more evidence to come about this medicine. 
The European Medicines Agency will review any new information on the medicine and this package 
leaflet will be updated as necessary. 
 
Detailed information on this medicine is available on the European Medicines Agency web site: 
http://www.ema.europa.eu 
 
------------------------------------------------------------------------------------------------------------------------- 
The following information is intended for medical or healthcare professionals only: 
As with all injectable vaccines, appropriate medical treatment and supervision should always be 
readily available in case of a rare anaphylactic event following the administration of the vaccine. 
 
HUMENZA consists of 2 separate vials:  
- One vial containing the antigen (suspension) 
- One vial containing the adjuvant (emulsion) 
Before use, the two components should be mixed. 
 
Instructions for mixing the vaccine: 
1. Before extemporaneous mix, the two vials (antigen and adjuvant) should be allowed to reach 

room temperature and must be gently swirled between hands and inspected visually for any 
foreign particulate matter and/or abnormal physical appearance. In the event of either being 
observed (including rubber particles from the stopper), the vaccine should be discarded. 

2. The vaccine is mixed by withdrawing with a sterile syringe and needle the entire content of the 
antigen vial and adding it into the adjuvant vial. 

3. After the addition of the antigen to the adjuvant, the mixture should be gently shaken by at least 
5 rotating movements. After mixing, the vaccine is a white opaque emulsion. 

4. The volume of HUMENZA after mixing is at least 6 ml and allows the withdrawal of several 
doses (multidose vial). For the dose to be administered, see recommended posology in section 3 
“How HUMENZA is given”. 

5. After mixing HUMENZA should be stored in a refrigerator (2°C-8°C) (never place in the 
freezer) and should be used within 24 hours. 

6. To facilitate tracking and timely disposal of partially used vials, it is suggested that the date and 
hour of mixing be clearly written on the label of adjuvant vial. 

 
Instructions for the administration of the vaccine: 
1. Before injection the vaccine should be allowed to reach room temperature by gently swirling the 

vial between hands (not more than 5 minutes). 
2. Prior to each administration, the multidose vial should be gently shaken by at least 5 rotating 

movements. 
3. The content of the multidose vial as well as the content of the syringe after withdrawal should 

be inspected visually. The vaccine is of a white opaque emulsion appearance. If deviations from 
this description and/or any foreign particulate matter are observed (including rubber particles 
from the stopper), the vaccine should be discarded. 



Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d

 
39 

4. Each vaccine dose of 0.5 ml or 0.25 ml (half-dose) is withdrawn with a new sterile syringe for 
injection and administered intramuscularly. 

 
HUMENZA should under no circumstances be administered intravascularly. 
 
A partially used multidose vial must be discarded immediately if: 
- Sterile dose withdrawal has not been fully observed. 
- There is any suspicion that the partially used vial has been contaminated. 
- There is visible evidence of contamination, such as change in appearance. 
 
In order to keep the traceability of the product received by each vaccinee the name of the vaccine and 
the lot number should be recorded by using the stickers provided in the pack containing both the 
antigen and adjuvant vials. 
Any unused product or waste material should be disposed of in accordance with local requirements.  
 
 


	SUMMARY OF PRODUCT CHARACTERISTICS
	A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE ANDMANUFACTURING AUTHORISATION HOLDERS RESPONSIBLE FOR BATCHRELEASE
	B. CONDITIONS OF THE MARKETING AUTHORISATION
	C. SPECIFIC OBLIGATIONS TO BE FULFILLED BY THE MARKETINGAUTHORISATION HOLDER
	A. LABELLING
	B. PACKAGE LEAFLET